Clinical trials: Empagliflozin
Diabetes Mellitus, Type 2
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1…
- Trial name
- NCT03993132
- Testing
- Empagliflozin, Liraglutide
- Where
- Denmark
- Volunteers
- 26,774 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations
The primary objective of this exploratory meta-analysis is to evaluate the frequencies, incidence rates, and hazard ratios of lower-limb amputation (LLA) events (primary outcome) and of adverse events related to amputation…
- Trial name
- NCT04937816
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 16,746 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale
This study aims at exploring the use of Dapagliflozin and Empagliflozin in children and adolescents 6-18 years old with heart failure.
- Trial name
- NCT06012266
- Testing
- Dapagliflozin tablet, Empagliflozin Tablets
- Where
- 3 sites in Switzerland, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Genetic Polymorphisms, Heart Failure
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown further reductions in heart failure hospitalization, cardiovascular events, and mortality, especially for heart failure patients.
- Trial name
- NCT06201000
- Testing
- SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- October 6 University
Healthy Subjects
Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose.
- Trial name
- NCT06232239
- Testing
- Empagliflozin-Test product, Empagliflozin-Reference product
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bio-innova Co., Ltd
Type 2 Diabetes Mellitus
A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379
This is a randomized, open-label, single dose, crossover, phase Ⅰ trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-379 in healthy volunteers
- Trial name
- NCT06204107
- Testing
- CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetic Kidney Disease
Treatment of Patients With Diabetic Kidney Disease
Due to irrespective of the limitations associated with estimated glomerular filtration rate (eGFR), it is crucial to develop new treatments that can effectively address these concerns.
- Trial name
- NCT06187493
- Testing
- lisinopril, enalapril, dapagliflozin, empagliflozin
- Volunteers
- 70 people
- Sponsor
- Assiut University
Obesity, Pre-diabetes
SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue.
- Trial name
- NCT04907214
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Vanderbilt University Medical Center
Type2 Diabetes Mellitus
Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition
An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single oral dose bioequivalence study of Empagliflozin 25 mg film coated tablets of Humanis, Turkey and Jardiance (Empagliflozin)…
- Trial name
- NCT06180109
- Testing
- Empagliflozin film coated tablets, Jardiance film-coated tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
This is a study in Chinese adults with type 2 diabetes. The study is open to people who take insulin but still have too high blood sugar levels. Participants may additionally be taking up to 2 other medicines for their diabetes.
- Trial name
- NCT04233801
- Testing
- Empagliflozin
- Where
- 24 sites in China
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Non-alcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
Non-alcoholic fatty liver disease (NAFLD) is a global epidemic with a prevalence of 25%. Currently therapies for NAFLD patients without diabetes mellitus (DM) are limited, and are associated with various adverse side effects.
- Trial name
- NCT04642261
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 98 people
- Sponsor
- The University of Hong Kong
Diabetes Mellitus, Type 2
DIA_CENTRAL:T2D Treatment Pattern in Central Europe
This is a non-interventional study using existing data including medical chart review.
- Trial name
- NCT03807440
- Testing
- Empagliflozin, Sodium Glucose Transporter 2 inhibitor, Dipeptidyl-peptidase 4 inhibitor
- Where
- 177 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 4,083 people
- Sponsor
- Boehringer Ingelheim
New Onset Diabetes After Transplant, Kidney Transplant; Complications
Efficacy and Safety of Empagliflozin in NODAT
This is an open label, randomized controlled study. We'd like to access the safety and effects of empagliflozin compared with linagliptin in new-onset diabetes after kidney transplantation patients.
- Trial name
- NCT03642184
- Testing
- Empagliflozin, Linagliptin
- Where
- China
- Volunteers
- 6 people
- Sponsor
- RenJi Hospital
Diabetic Neuropathy Peripheral
Empagliflozin in Treatment of Peripheral Diabetic Neuropathy
The aim of the study is to investigate the possible protective effect of empagliflozin in patients with type 2 diabetes mellitus with diabetic peripheral neuropathy and not on SGLT2 inhibitors treatment.
- Trial name
- NCT05977465
- Testing
- Empagliflozin 25 MG
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tanta University
Coronary Artery Disease
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)
Sodium-glucose contrasporter-2 (SGLT-2) inhibitors make up an antidiabetic medication that promotes glycosuria. They are known to have an indirect reduction in cardiovascular complications, based on a series of in-depth studies.
- Trial name
- EpiCAD (NCT06128096)
- Testing
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Where
- Malaysia
- Volunteers
- 360 people
- Sponsor
- Clinical Research Centre, Malaysia
Post-operative Atrial Fibrillation, CABG
Empagliflozin to Prevent Post-Operative Atrial Fibrillation
This is an interventional, double-blind, placebo controlled, multicenter, randomized clinical trial with allocation sequence concealment and blinded endpoint adjudication.
- Trial name
- EMPOAF (NCT06124937)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Iran
- Volunteers
- 492 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Heart Failure Acute, Ventilator Lung
SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
This study will explore the potential benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in preventing cardiac ischemia and cardiopulmonary edema in patients with acute decompensated heart failure during weaning from…
- Trial name
- NCT06142474
- Testing
- SGLT2 inhibitor
- Where
- Taiwan
- Volunteers
- 450 people
- Sponsor
- National Taiwan University Hospital
Lupus Nephritis
Assessment of Safety and Efficacy of SGLT2is Among LN Patients
The aim of this study is to assess the safety and efficacy of SGLT2is among LN patients.
- Trial name
- NCT06113900
- Testing
- Dapagliflozin 10mg Tab orally once daily
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Cancer
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin
Doxorubicin induced cardiomyopathy is the most common and serious side effect associated with doxorubicin treatment in cancer patients receiving doxorubicin.
- Trial name
- NCT06103279
- Testing
- Empagliflozin 10 MG
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
Diabetes Mellitus, Kidney Transplant; Complications
Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus
This EmLina Renal trial is an investigator initiated, single-center, prospective, open-label, randomized clinical study to examine the safety and effect of empagliflozin 25 mg once a day vs.
- Trial name
- EmLina Renal (NCT06098625)
- Testing
- Empagliflozin 25 MG, Linagliptin 5 mg Oral Tablet
- Volunteers
- 200 people
- Sponsor
- Medanta, The Medicity, India